Eli Lilly and Co (LLY)

Industry Drug Manufacturers - General
This stock can be held in an Investment ISA and an Investment Account
Sell

$747.00

Buy

$747.80

arrow-down$-9.51 (-1.26%)

Prices updated at 14 May 2025, 00:59 EDT
| Prices minimum 15 mins delay
|
Prices in USD
Eli Lilly and Co is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. It discovers, develops, manufactures, and sells human pharmaceutical products and animal health products.
S&P 500
arrow-up0.72%
NYSE
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Drug Manufacturers - General
Chairman
Mr. David A. Ricks
CEO
Mr. David A. Ricks
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
47,000
Head office
Lilly Corporate Center
Indianapolis
United States
46285
mobile
+1 317 276-2000
letter
jfletcher@lilly.com
computer
Company website

Key personnel

Owner name
chevron-l-regular
chevron-r-regular
Salary
Ms. Gabrielle Sulzberger, J.D.,M.B.A.
Independent Director
0.12m
Mr. Jon Erik Fyrwald
Independent Director
0.12m
Mr. Juan R. Luciano
Lead Independent Director
0.18m
Mr. Jon R. Moeller
Independent Director
0.01m
Dr. Mary Lynne Hedley,PhD
Independent Director
0.12m
Mr. Ralph Alvarez
Independent Director
0.14m
Dr. Katherine Baicker, PhD
Independent Director
0.14m
Mr. David A. Ricks
Chairman of the Board, President and Chief Executive Officer
1.69m
Dr. William G. Kaelin, Jr,M.D.
Independent Director
0.14m
Mr. Donald A. Zakrowski
Senior Vice President, Finance and Chief Accounting Officer
-
Mr. Jamere Jackson
Independent Director
0.15m
Mr. Jacob S. Van Naarden
Executive Vice President and President, Lilly Oncology
0.89m
Ms. Kimberly H. Johnson
Independent Director
0.12m
Ms. Anat Hakim
Executive Vice President, General Counsel and Secretary
1.00m
Dr. Daniel M. Skovronsky, M.D.,PhD
Executive Vice President, Chief Scientific Officer and President, Lilly Research Laboratories and Lilly Immunology
1.43m
Mr. Lucas Montarce
Executive Vice President and Chief Financial Officer
0.66m
Ms. Anne E. White
Executive Vice President and President, Lilly Neuroscience
-
Mr. Patrik Jonsson
Executive Vice President and President, Lilly Cardiometabolic Health; President, Lilly USA
-
Mr. Ilya Yuffa
Executive Vice President; President, Lilly International
-
Mr. Edgardo Hernandez
Executive Vice President and President, Manufacturing Operations
-
Mr. Diogo Rau
Executive Vice President, Chief Information Officer and Chief Digital Officer
-
Mr. Eric Dozier
Executive Vice President and Chief People Officer
-
Ms. Melissa Seymour
Executive Vice President, Global Quality
-

Top 5 shareholders

Owner name
chevron-l-regular
chevron-r-regular
No. of shares
Lilly Endowment Inc96,016,978
Vanguard Group Inc74,248,997
BlackRock Inc65,229,114
PNC Financial Services Group Inc51,303,099
Capital Research and Management Company42,740,456

Director dealings

Date
chevron-l-regular
chevron-r-regular
Action
16 Dec 2024-
16 Dec 2024-
16 Dec 2024-
16 Dec 2024-
16 Dec 2024-
18 Nov 2024-
18 Nov 2024-
18 Nov 2024-
18 Nov 2024-
18 Nov 2024-
18 Nov 2024-
18 Nov 2024-
18 Nov 2024-
18 Nov 2024-
18 Nov 2024-
18 Nov 2024-
18 Nov 2024-
18 Nov 2024-
18 Nov 2024-
18 Nov 2024-
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.